CTRI/2010/091/000201已完成2 期
A Prospective, Randomized (3:1), Comparative, Blinded, Placebo-Controlled, Three Different Intravenous Dose, Phase 2a Study of the Safety and Efficacy of CMX-2043 in Subjects Undergoing PCI and Peri-Operative Reperfusion Treatment (SUPPORT-1)
试验速览
- 阶段
- 2 期
- 状态
- 已完成
- 发起方
- Ischemix LLC
- 入组人数
- 142
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
入选标准
- •1. Male or female subjects of 18 to 70 years of age (both inclusive).
- •2. Subjects with stable coronary artery disease, documented by coronary angiography within 28 days of PCI procedure.
- •3. Subjects who have stable coronary artery disease undergoing elective PCI (planned placement of a single stent of ≥ 18 mm or multiple stents).
- •4. Female subjects:
- •a. Surgically sterile with documented bilateral tubal ligation or hysterectomy
- •b. documented to be post-menopausal for at least one year
- •c. if of child-bearing potential, practicing an acceptable method of birth control for the duration of the study as judged by the investigator, such as condoms, foams, jellies, diaphragm, intrauterine device or abstinence.
- •5. Absence of ST segment depression >1.0 mm and absence of ST elevation >1.0 mm in any lead on the baseline 12-lead ECG.
- •6. Subjects with CK-MB and troponin-T levels lower than the upper limit of normal as determined at local site laboratory.
- •7. Subjects free of acute injuries or illnesses that in the opinion of the investigator could increase the risk of the study to the subject or obscure the interpretation of results.
- •8. Subjects willing to undergo pre-and post-study physical exams and laboratory investigations.
- •9. Subjects willing to provide signed written informed consent form
排除标准
- •1. Subjects with unstable angina (angina at rest, worsening frequency, duration of angina) or other signs of unstable coronary artery disease.
- •2. Subjects who had had an MI within 14 days prior to the PCI procedure.
- •3. Subjects with conditions that contraindicate the PCI (e.g. coagulopathy, valvular disease, PVD).
- •4. Subjects with history of TIA/stroke within 90 days or any intracranial bleed.
- •5. Subjects with plasma creatinine level ≥ 1.5 times the upper limit of normal.
- •6. Subjects with an active history of psychiatric disorders that is likely to limit the validity of consent to participate in the study or limit the ability to comply with the protocol requirements.
- •7. Subjects with a history of alcohol or drug abuse.
- •8. Subjects with documented history of human immunodeficiency virus (HIV), or Hepatitis B (HBsAg) or Hepatitis C (HCV) virus positive.
- •9. Subjects with uncorrected clinically significant abnormalities of clinical laboratory tests who in the investigators opinion will interfere with the study conduct.
- •10. Subject with chronic diseases considered by the anesthetist unfit for surgery and/or who in the opinion of the investigator will increase the risk of the study or obscure the interpretation of results.
- •11. Subjects who have participated in a clinical study within 1 month or are currently participating in a clinical study of an investigational agent.
- •12. A known history of drug hypersensitivity to CMX-2043 or any of the excipients of CMX-2043.
- •13. Any other medical condition or reason that, in the Investigator's opinion, makes the subject unsuitable to participate in this clinical trial.
研究者
相似试验
已完成
3 期
A clinical study to evaluate efficacy & safety of a novel nasal spray fixed dose combination of Azelastine hydrochloride & Mometasone furoate monohydrate compared with individual Azelastine hydrochloride 137mcg & Mometasone Monohydrate 50mcg nasal spray in patients with perennial Allergic Rhinitis.CTRI/2014/02/004439Cipla Ltd120
进行中（未招募）
3 期
Clinical study to evaluate the efficacy and safety of FluticasoneFuroate and Oxymetazoline Hydrochloride Nasal Spray 27.5 / 50 mcg as compared to Fluticasone Furoate Nasal Spray 27.5mcg in patients with allergic rhinitisCTRI/2020/10/028347Cadila Healthcare Limited
尚未招募
4 期
A post marketing surveillance trial to study the safety and efficacy of two drugs, Neupeg and Neulastim in female patients with advanced breast cancerCTRI/2010/091/000109Intas Biopharmaceuticals Limited100
已完成
4 期
A clinical trial to study the effect of Desmopressin Intranasal Solution BP (Mfd. by Biodeal Laboratories Pvt. Ltd.) Vs. Desmopressin Intranasal Solution BP (Mfd. by Ferring Pharmaceuticals Ltd.) in patients diagnosed with Central Cranial Diabetes Insipidus.CTRI/2010/091/001415Biodeal Laboratories Pvt. Ltd 508, G.I.D.C Estate, Wadhwan city, Dist Surendranagar,Gujarat - 36303562
已完成
3 期
Evaluation of local application of Myostaal liniment in strengthening muscles in knee arthritisCTRI/2020/11/029031Solumiks Herbaceuticals Limited70